JK07
JK07 (SAL007) is a conjugate of an antagonistic HER3 antibody and the EGF-binding domain of NRG-1. JK07 utilizes the NRG1 EGF-like domain to stimulate ErbB4 phosphorylation and HER2/HER4 dimerization and activate AKT signaling, while its antibody component antagonizes ErbB3, blocking NRG-1-induced HER3 dimerization and reducing ErbB3-mediated toxicity. JK07 enhances angiogenesis, reduces cardiac fibrosis and type I Collagen deposition, and improves cardiac function after myocardial infarction. JK07 improves left ventricular ejection fraction and attenuates left ventricular dilation in heart failure models. JK07 can be used for research on coronary microvascular dysfunction and head and neck squamous cell carcinoma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[3]|
HER2 |
ErbB4 |
HER3 |
In Vitro
JK07 (0.875-14 nM HER3) binds HER3 across species, with approximately 10-fold lower affinity for rodent HER3 than for primate HER3/hHER3[3].
JK07 attenuates NRG-1-induced HER2/HER3 dimerization in U2OS cells[3].
JK07 induces HER2/HER4 dimerization in U2OS cells to an extent comparable to that of NRG-1[3].
JK07 (stimulation for 15 minutes) increases AKT phosphorylation in iCell cardiomyocytes to an extent comparable to that of NRG-1[3].
JK07 (16 nM; 15-minute stimulation) increases p-AKT[3] in iCell and rat primary cardiomyocytes.
JK07 selectively activates ErbB4 in vitro, with an ErbB4 activation level comparable to that of NRG-1, while attenuating ErbB3 activation[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
JK07 (1 mg/kg in Study 1 or 0.1-0.3 mg/kg in Study 2; i.v.; once weekly; 2 or 9 weeks) improves systolic function in rhesus macaques with spontaneous HFrEF across the two tested dosing regimens[3].
JK07 (1 mg/kg in Study 1 or 0.1-0.3 mg/kg in Study 2; i.v.; once weekly; 2 or 9 weeks) improves diastolic dysfunction class in rhesus macaques with spontaneous HFpEF across the two tested dosing regimens[3].
JK07 increases EF by at least 5% absolute in 7/10 rhesus macaques with HFrEF, comparable to sacubitril/valsartan[4].
JK07 improves diastolic dysfunction by at least one grade in 6/10 rhesus macaques with HFpEF, superior to Sacubitril (HY-15407)/Valsartan (HY-18204)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Aachener minipig (castrated male, 6 months old)[2]
-
Dosage:0.3 mg/kg
-
Administration:i.v.
-
Result:IMR was 11.3 mmHg·s; DOCA-only pigs had 19.9 mmHg·s and controls had 14.5 mmHg·s.
dP/dt_max was 3107.3 mmHg/s; DOCA-only pigs had 4455.5 mmHg/s and controls had 2415.5 mmHg/s.
dP/dt_min was significantly lower in DOCA versus CTRL; no difference was found between the other DOCA group and CTRL or DOCA.
No between-group differences were observed for coronary flow reserve, resting full-cycle ratio, fractional flow reserve, mean transit time at rest or hyperemia, baseline resistance index, or relative resistance ratio.
Interstitial left ventricular fibrosis was 2.1%; DOCA-only pigs had 5.4%.
Perivascular fibrosis did not differ between groups.
Echocardiographic myocardial hypertrophy was not decreased and atrial dilatation was not prevented; IVSd and LVPWd were increased versus CTRL in both DOCA groups, and LAVd was increased in DOCA versus CTRL.
Cardiomyocyte cross-sectional area remained greater than CTRL in both DOCA groups, with no difference between the DOCA groups.
Capillary density, pericyte coverage, capillary area or size, microvascular vessel thickness, inflammatory cytokines, and endothelial activation were not affected.
-
Animal Model:NOD/SCID (17.5-21.5 g)[3]
-
Dosage:1 mg/kg and 10 mg/kg
-
Administration:i.v.
-
Result:At Day 21 post-dose, tumor growth inhibition was 19.2% at 1 mg/kg and 56.2% at 10 mg/kg.
-
Animal Model:Sprague Dawley (male; 273-315 g)[3]
-
Dosage:1, 3, and 10 mg/kg
-
Administration:i.v.
-
Result:LVEF at week 2/week 4 was 65.7% / 64.6% for 1 mg/kg, 68.4% / 67.5% for 3 mg/kg, and 71.7% / 73.9% for 10 mg/kg.
ΔEF at week 2/week 4 was 16.2% / 14.7% for 1 mg/kg, 26.3% / 26.9% for 3 mg/kg, and 33.2% / 36.6% for 10 mg/kg.
ΔLVIDd at week 2/week 4 was -0.28 / -0.06 mm for 1 mg/kg, -0.82 / -0.20 mm for 3 mg/kg, and -1.1 / -0.54 mm for 10 mg/kg.
ΔLVIDs at week 2/week 4 was 0.67 / 0.48 mm for 1 mg/kg, 1.29 / 1.06 mm for 3 mg/kg, and 1.72 / 1.65 mm for 10 mg/kg.
Exercise distance was 76.9 m at 1 mg/kg, 52.1 m at 3 mg/kg, and 65.2 m at 10 mg/kg.
Collagen I was 9.42% at 1 mg/kg, 6.35% at 3 mg/kg, and 6.00% at 10 mg/kg; collagen III was 5.5%, 5.15%, and 5.13%, respectively; collagen I/III ratio was 1.82, 1.13, and 1.21, respectively.
At 4 weeks, pathological changes in the myocardial infarction marginal zone were partially alleviated in a dose-dependent manner, with reduced necrotic cells, narrowed interstitial spaces, and recovery of myocardial fiber arrangement toward normal versus vehicle.
- Kinase activity and phosphorylation assays
- Fibrosis/Collagen Morphometry
- Western Blot
- Collagen: Sirius Red Staining
- Human pluripotent stem cell endothelial-cell differentiation
- Vascular/Branching Fractal Analysis
- Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
- Endothelial Tube Formation Assay
- Research Protocol for Cardiovascular Diseases
- Protocol for Kinase activity and phosphorylation assays
- Endothelial Cell Migration/Angiogenic Sprouting Assay
Product Details
-
Synonyms SAL007
Product Properties
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)